(MENAFN- Investor Brand Network) Cybin (NYSE American: CYBN) (NEO: CYBN) , a clinical-stage neuropsychiatry company, summarized its 2024 accomplishments and detailed upcoming 2025 milestones. CEO Doug Drysdale highlighted advancements in its pipeline of tryptamine serotonin receptor agonists, including CYB003, a deuterated psilocin program for major depressive disorder (“MDD”), and CYB004, a deuterated dimethyltryptamine in intramuscular form for generalized anxiety disorder (“GAD”). In March 2024, CYB003 received FDA Breakthrough Therapy Designation, expediting its development and recognizing the unmet need in MDD treatment. Results from a Phase 2 study of CYB003 in MDD showed a 100% response rate and 71% remission rate, leading to the initiation of the multinational Phase 3 PARADIGMTM program. Additionally, a Phase 2 proof-of-concept study for CYB004 in GAD commenced. For 2025, Cybin anticipates topline data from the CYB004 Phase 2 study in early 2025 and the initiation of the EXTEND and EMBRACE components of the PARADIGM Phase 3 program.

To view the full press release, visit

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin's goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit
.

NOTE TO INVESTORS:
The latest news and updates relating to CYBN are available in the company's newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire
(“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 70+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text“Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:
/Disclaimer

PsychedelicNewsWire
Austin, Texas

512.354.7000 Office
[email protected]

PsychedelicNewsWire is powered by
IBN

MENAFN13012025000224011066ID1109085554